Articles tagged with Brain Tumors
Researchers at Michigan Medicine developed a nanoparticle-based inhibitor that successfully triggers the immune system to eliminate brain tumors in mouse models. The approach breaks the shield built by glioma cells around the immune system, allowing the immune cells to attack and delay tumor progression.
Researchers have developed a novel therapeutic strategy for treating glioblastoma using allogenic stem cells that can target and kill tumor cells. The therapy demonstrated profound efficacy in preclinical models, with 100% of mice living over 90 days after treatment.
Researchers discovered that neurons carrying a mutation in the Nf1 gene are hyperexcitable and suppressing this hyperactivity with lamotrigine stops tumor growth in mice. The study provides an explanation for why some people with NF1 lack optic gliomas or neurofibromas, highlighting the critical role of neurons in tumor biology.
Researchers are developing a novel MRI nanotechnology that targets specific markers in solid tumours, including high-grade brain cancers. The new imaging technology has shown promising preclinical results and is set to be tested in a first-in-human clinical trial.
The new center aims to advance a groundbreaking combination of focused ultrasound and cancer immunotherapy, potentially revolutionizing cancer treatment. The partnership will focus on overcoming existing limitations of immunotherapy and expanding treatment options for various types of cancer.
The new ASTRO guideline provides guidance on radiation therapy for brain metastases, including evidence-based recommendations for multidisciplinary planning and delivery of advanced techniques to manage intact and resected brain tumors. The guideline aims to improve quality of life and outcomes for patients with brain metastases.
A new study from McGill University finds that people living near regions prone to wildfires may have a higher incidence of lung cancer and brain tumors. Exposure to carcinogenic wildfire pollutants on a chronic basis increases the risk of certain cancers, according to researchers.
A new drug called abemaciclib has been shown to halt the growth of recurring brain tumors in patients with aggressive meningiomas. The treatment targets a common molecular pathway that enables cells to divide rapidly and come back after surgery, allowing researchers to predict recurrence more accurately.
Researchers created patient-derived models of brain metastases that recapitulate human disseminated disease, reflecting clinical manifestations and biological characteristics. These models can be used to test therapeutic value of different treatments and explore new approaches tailored to each patient.
A novel inhibitor has been discovered that stalls a critical enzyme inside tumour cells, locking them in place and preventing invasion into healthy tissue. The findings hold promise for the development of metastasis-blocking agents.
A study from the University of Pittsburgh found that methionine restriction can slow down the growth of difficult-to-treat brain tumors in children, known as diffuse midline gliomas. The researchers discovered that these tumors are uniquely dependent on methionine, an amino acid, and that depleting it can repress cancer cell growth.
Researchers have created a Russian-language protocol for functional magnetic resonance imaging (fMRI) to map individual language areas before neurosurgical operations. The study successfully validated the protocol in a control group, showing its ability to comprehensively map brain regions and reveal lateralisation of language function.
City of Hope researchers present new developments in cell therapy for acute myeloid leukemia and non-small cell lung cancer. A novel smoking cessation program increases patient desire to quit with personalized counseling.
Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.
Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.
Scientists have discovered anticancer substances in kudzu roots and soy molasses that can fight cancer, especially when chemotherapy or surgery are dangerous. The isoflavonoids in these plant extracts mimic human estrogen and bind to free radicals, leading to various diseases including cancer formation.
Researchers develop innovative non-contact agitation technology to assess motility and invasive capacity of cancer cells in tissue sections. The study reveals significant increases in Rac/Cdc42 activity in tumor areas, with stronger correlations found in advanced cancer stages.
Researchers collected hundreds of cerebrospinal fluid samples from patients with Diffuse Midline Glioma, tracking changes in cell-free tumor DNA over time. The findings suggest that this method could provide data about tumors sooner than MRIs alone, allowing clinicians to address aggressive brain cancer more effectively.
Researchers have found that immune checkpoint inhibitors like pembrolizumab can slow disease progression in patients with high-grade meningiomas. The study showed that nearly half of all patients were alive and without evidence of disease progression for at least 6 months after treatment.
Researchers developed a computational approach called CellTrek to combine parallel gene-expression profiling methods, creating spatial maps at single-cell resolution. The tool provides detailed information on individual cell types' location within tissues, enabling unique biological insights.
Research led by Adam Green, MD, shows that the youngest patients with brain tumors (ages 0-3 months) have about half the five-year survival rate as children ages 1-19. The study analyzed population-based data for almost 14,500 children and found significantly poorer outcomes among the youngest patients.
Researchers found that the Klotho gene can suppress glioblastoma cell viability and induce apoptosis, leading to a significant decrease in tumor growth. The study contributes to the development of new diagnostic and treatment approaches for malignant brain tumors.
Researchers at Johns Hopkins Medicine discovered 110 genes, circular RNAs, lipids and metabolites that differ between medulloblastoma patients' cerebrospinal fluid and healthy controls. These findings provide proof of principle for novel biomarkers to detect and track the disease.
Researchers at IBiS have developed a new treatment that completely eliminated glioblastoma tumors in animal models, offering a new therapeutic option against this aggressive disease. The therapy combines the use of ADI-PEG20 with focal brain radiotherapy and has shown promising results without side effects.
Researchers have developed a low-cost, easy-to-use focused ultrasound device that can precisely target the mouse brain. The $80 device, created using a 3D printer, has been shown to achieve sub-millimeter targeting accuracy and improve drug delivery outcome.
Researchers have designed METPlatform, a drug screening platform compatible with patient biopsies, to investigate patients' own tumour tissue. The platform has identified new therapeutic targets and biomarkers for aggressive brain metastases, suggesting HSP90 inhibitors as potential treatments.
Four IIT researchers have been awarded €150,000 each from the European Research Council to develop groundbreaking technologies addressing health challenges, such as tumours, blindness, and amputations. Their projects aim to substitute critical raw materials in electronics and create multisensory systems for visually impaired infants.
Researchers developed a method called 6mASCOPE that measures DNA tagging system accuracy and distinguishes bacterial from human DNA. The study found high levels of methylation in plant, fly, mouse, and human cells, but mostly attributed to contamination.
Scientists at University College London have developed a novel cancer therapy using magnetic seeds guided by an MRI scanner to heat and destroy tumours. The therapy, called MINIMA, has the potential to precisely treat hard-to-reach cancers with minimal side effects.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
Breakthrough research reveals Tuberous Sclerosis Complex arises from human-specific progenitor cells, explaining its pathology. Human-derived cerebral organoid models shed light on complex brain development and potential mechanisms for other diseases.
A new study by WVU researcher William Walker found that the blood-brain barrier is dynamic and more receptive to chemotherapy at night. This could lead to better treatment outcomes for patients with brain metastasis.
A UC researcher is leading three projects to study the genetic workings of deadly pediatric brain tumors, including DIPG. The goal is to understand how genes regulate blood vessels and develop more effective treatments. Researchers are also exploring a new drug that targets a specific genetic mutation.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.
Researchers found that zika virus injections destroyed brain tumors in mice and reduced tumor size in cerebral organoids, with immune cells alerting the system to its existence. This approach opens up prospects for virotherapy treatment of central nervous system tumors.
A phase 1 clinical trial found that the DNA methylome of aggressive brain tumors can be reprogrammed with L-methylfolate, a folic acid-like drug. The treatment showed improved median overall survival in patients with recurrent glioblastoma, paving the way for future epigenetic studies and potential immunotherapy combinations.
Researchers found that CBD shrinks glioblastoma tumors by reducing inflammation and restoring immune balance. The compound also suppresses key proteins involved in tumor growth and spread, making it a potential novel adjunct therapy for glioblastoma patients.
Researchers have discovered that HIV drugs may be effective in treating low-grade brain tumours, specifically meningioma and acoustic neuroma. High levels of HERV-K proteins were found to stimulate the growth of these tumours, and targeted drugs have been identified to reduce their growth.
Research reveals that the parietooccipital fissure acts as an obstacle to glioma invasion, with tumor cells making a detour around it. This finding highlights the importance of this fissure in determining the invasion pattern of posterior medial temporal gliomas.
Researchers found that asthma causes immune cells to behave in a way that prevents brain tumor growth, suggesting a potential new therapeutic approach. The findings suggest reprogramming T cells to act like those in asthma patients could be a new treatment for brain tumors.
A prospective study found that MRI outperformed conventional tests and FDG PET/CT for various staging endpoints in SCLC. Whole-body MRI and FDG PET/MRI were more accurate than FDG PET/CT for assessing local invasion extent.
In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.
Investigators at Weill Cornell Medicine identified significant age-related differences in tumor characteristics across various cancers, suggesting potential for personalized treatment approaches. They found that tumors from younger patients showed advanced signs of aging and more mutations associated with aggressive disease.
A UCLA research team found that PD-1 blockade initially activates T cells and conventional dendritic cells in glioblastoma, but the immune microenvironment remains dominated by immunosuppressive cells. The study suggests that combining therapies targeting other checkpoint proteins and pathways may improve treatment outcomes.
Cleveland Clinic researchers found that verubecestat, an Alzheimer's disease treatment, reduces glioblastoma progression by reprogramming tumor-associated macrophages into tumor-suppressing macrophages. This transformation leads to increased phagocytosis of tumor cells and reduced tumor growth.
Researchers at Children's National Hospital have successfully developed a personalized T cell immunotherapy that targets and kills unique proteins in individual tumor cells. This approach, combining genetic sequencing and protein identification, offers a promising treatment option for children with hard-to-treat brain tumors.
A Mount Sinai study reveals that young adult cancer patients exhibit distinct genetic hallmarks and immune system responses compared to their older counterparts. These findings suggest personalized treatment approaches for young adults with various types of cancers.
Researchers identified 166 prognostic biomarkers from long non-coding RNAs, with one biomarker, HOXA10-AS, showing high effectiveness in categorizing gliomas as low- or high-risk. The study provides potential therapeutic targets and insights into cancer biology.
A study found that patients from ethnic minority groups had lower mortality rates compared to white British people. Patients from Indian, Pakistani, and other ethnic backgrounds were 16-30% less likely to die within one year of diagnosis.
A study found that arginine treatment improved outcomes in cancer patients with brain metastases, showing a complete or partial response in nearly 78% of patients. The amino acid may be useful as an anticancer therapy when combined with radiotherapy or other treatments.
A recent study published in PLOS ONE found that combining copper ions with a drug once used for treating alcoholism kills medulloblastoma cancer cells and prevents new ones from forming. The therapy also curtails the creation of cancer stem cells, which initiate tumor growth and recurrence.
Researchers at UBC and BC Cancer developed a new test to distinguish between high-risk medulloblastoma cases requiring radiation therapy and lower-risk cases. This test has the potential to improve diagnosis and future treatment of childhood brain tumours worldwide, reducing unnecessary side effects and increasing cure rates.
Researchers at Queen Mary University of London have discovered a new way to analyze diseased and healthy cells from the same patient, revealing potential targets for individualized treatments. The study's findings could also help predict patient response to current drugs, leading to improved survival rates.
A team of researchers from Japan has developed a platform using nanofibers to capture and control the migration of brain tumor cells, including glioblastoma multiforme. The study found that varying fiber densities can slow or speed up cell movement, leading to the creation of 'cell traps' that can restrict tumor cell growth.
A new study found that translocator protein 18 kDa (TSPO) correlates with worse survival outcomes in male glioblastoma patients compared to females. The variation in the protein's structure is associated with shorter overall and progression-free survival times, suggesting its potential as a prognostic biomarker.
Researchers at Sunnybrook Health Sciences Centre have successfully delivered antibody therapy to breast cancer metastases in the brain using focused ultrasound. The treatment, which temporarily opens the blood-brain barrier, has shown promising results with tumor size reductions of up to 21% in patients.
A new antibody delivery technology enhances anti-PD-L1 antibody accumulation in glioblastoma by 33-fold, achieving a 60% complete response rate with long-term immune memory. The technology also suppresses immune-related adverse events.
Researchers found that metformin suppressed glucose metabolism and killed cancer cells in group A posterior fossa ependymomas, a type of childhood brain tumor. The study's senior author believes this opens a promising possibility for therapeutic suppression of the epigenetic changes driving these tumors.
Researchers developed a gel made of fibrin that improved the effectiveness of CAR-T cell immunotherapy for glioblastoma by enhancing T cell distribution and preventing tumor recurrence. In mouse studies, the gel showed promising results, with 64% of treated mice being tumor-free after 94 days.
Researchers at Weill Cornell Medicine have profiled individual cells from patients' brain tumors in unprecedented detail, revealing distinct states and programming marks that could be targeted with future drugs. The study offers insights into glioma dynamics and may lead to better detection, staging, monitoring, and treatment methods.